Payment & Shipping Terms:
mind enhancing supplements
NSI-189 Phosphate Health Nootropic Supplements CAS 1270138-40-3
NSI-189 is a benzylphiperizine-aminiopyridine, nootropic and neurogenic research chemical created by Neuralstem, Inc. that was derived from pyrazine and nicotinamide. Studies have shown that it stimulates neurogenesis of human hippocampus-derived neural stem cells in vivo and vitro .
In healthy adult mice, NSI-189 has been shown to increase the hippocampal volume by 20% and reverse behavioral symptoms in mouse depression models, meaning at the source it could address depression . The hippocampus is responsible for spatial navigation, along with the consolidation of information from short-term memory to long-term memory.
|Product name||nsi-189 phosphate|
|Appearance:||White fine powder|
|Application||Medicine or health care products|
Tests have shown that NSI-189 significantly improved behavioral responses that are associated with depression . In humans it may counter hippocampal atrophy which is seen in disorders such as MDD, reversing their symptoms. A phase 1B randomized, double-blind, placebo-controlled, multiple-dose escalation study conducted over a 28 day period showed behavioral efficacy in 24 patients who were orally administered NSI-189 .
Phase 1A tested escalating doses of the neurogenic compound NSI-189 in healthy patients, 1B tested the safety of escalating doses in 24 depressed patients over the course of 28 days . During phase 1B patients were administered 40 mg per day, and 80 mg per day, and at the highest dose 120 mg per day. No serious adverse events occurred during the time of the study and the drug was well tolerated. Reduction in cognitive and depressive symptoms were observed across all measures for the two lower doses 40 mg/day and 80 mg/day but not for the highest dose 120 mg/day .
The main limitations of the phase 1B study was the small sample size of each cohort, and also the fact that efficacy analyses were not the primary focus. In summary, NSI-189 looks promising as a potential treatment for MDD in a Phase 1B, double-blind, randomized, placebo-controlled, multiple-dose study with three ascending cohorts.
The preliminary findings are supportive of the view that neurogenesis-based platforms are capable of identifying auspicious new treatments for MDD. However, further studies are imperative to confirm the preliminary observations. Neuralstem intends to pursue further clinical trials for various encephalopathic conditions including post-traumatic stress disorder, traumatic brain injury, and natural aging.
Q1: Are you a manufacturer ?
A: Yes, We manufacture bulk products in our factory located in Jiayu, Hubei, and produce small quantity and customer synthesis products in our lab located in Wuhan. But we also do some trading business.
Q2: What`s your delivery
A: We send goods in 3 working day after receiving your payment by DHL, FEDEX, TNT, EMS, AIR OR SEA as you request, usually you can find shipping details in 3 to 5 working days after your payment.
Q3: What certificates and documents do you offer?
A: Some technical paperwork is available, such as COA, HNMR, HPLC, LC-MS etc.
Contact Person: Amy